OSD
Mark Quick, Executive Vice President – Corporate Development discusses with Greater Copenhagen Life Science the benefits to small, mid-size pharma and even big pharma with choosing this option.
Greater Copenhagen Life Science, March Issue 2017
The trend of life science pharmaceutical companies partnering up with contract development and manufacturing organisations (CDMO) has grown as newer and smaller companies turn away from investing in large scale in-house production and instead outsource manufacturing of their products from the beginning.
There is an opportunity for consolidation to help customers reduce their supplier base.